G. Parker

发表

eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)

P. A. Thompson, K. Webster, Katti A. Jessen, 2015 .

Abstract 596: eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity

P. A. Thompson, C. Stumpf, K. Webster, 2017 .

Abstract PR11: eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade

P. A. Thompson, C. Stumpf, K. Webster, 2017 .

RDE-4 preferentially binds long dsRNA and its dimerization is necessary for cleavage of dsRNA to siRNA.

B. Bass, D. Eckert, G. Parker, 2006, RNA.

dsRNA binding properties of RDE-4 and TRBP reflect their distinct roles in RNAi.

B. Bass, T. Maity, G. Parker, 2008, Journal of molecular biology.

Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.

P. A. Thompson, C. Stumpf, Qing Han, 2018, Journal of medicinal chemistry.

Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies

P. A. Thompson, K. Webster, N. Young, 2017 .

Abstract 3757: Novel monoclonal antibodies for the analysis and isolation of Lgr5 positive cells.

A. Bosio, O. Hardt, D. Agorku, 2013 .